Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Transfusion Dependent Thalassemia
NCT03651102Phase 3Completed
- Sponsor
- Blood Diseases Clinic
- Start
- Jan 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of thalidomide in thalassemia, sponsored by Blood Diseases Clinic. Primary endpoints: Haemoglobin Level at 24 months, Response Rate at 24 months and 1 more. Started Jan 2018; status: completed.
02
Drugs
thalidomide
03
Conditions
thalassemia
Beyond the preview
Go deeper on NCT03651102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651102.